BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35595819)

  • 1. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver.
    Tang W; Zhou J; Yang W; Feng Y; Wu H; Mok MTS; Zhang L; Liang Z; Liu X; Xiong Z; Zeng X; Wang J; Lu J; Li J; Sun H; Tian X; Yeung PC; Hou Y; Lee HM; Lam CCH; Leung HHW; Chan AWH; To KF; Wong J; Lai PBS; Ng KKC; Wong SKH; Wong VWS; Kong APS; Sung JJY; Cheng ASL
    Cell Mol Immunol; 2022 Jul; 19(7):834-847. PubMed ID: 35595819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
    Song Q; Zhang X; Liu W; Wei H; Liang W; Zhou Y; Ding Y; Ji F; Ho-Kwan Cheung A; Wong N; Yu J
    J Hepatol; 2023 Dec; 79(6):1352-1365. PubMed ID: 37459922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
    Hymel E; Vlock E; Fisher KW; Farazi PA
    PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet.
    Chun HJ; Shim YJ; Kwon YH
    J Nutr Biochem; 2022 Feb; 100():108869. PubMed ID: 34563665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
    Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
    Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.
    Ma C; Zhang Q; Greten TF
    FEBS J; 2018 Feb; 285(4):752-762. PubMed ID: 28857485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotic antigens stimulate hepatic natural killer T cells.
    Liang S; Webb T; Li Z
    Immunology; 2014 Feb; 141(2):203-10. PubMed ID: 24400795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces hepatocellular carcinoma.
    Li T; Weng J; Zhang Y; Liang K; Fu G; Li Y; Bai X; Gao Y
    Cell Death Dis; 2019 Aug; 10(8):619. PubMed ID: 31409773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice.
    Zheng S; Yang W; Yao D; Tang S; Hou J; Chang X
    Ann Med; 2022 Dec; 54(1):2233-2245. PubMed ID: 35950602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease.
    Komatsu G; Nonomura T; Sasaki M; Ishida Y; Arai S; Miyazaki T
    Exp Anim; 2019 May; 68(2):147-158. PubMed ID: 30487357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target.
    Liu D; Wong CC; Fu L; Chen H; Zhao L; Li C; Zhou Y; Zhang Y; Xu W; Yang Y; Wu B; Cheng G; Lai PB; Wong N; Sung JJY; Yu J
    Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
    Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
    Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
    Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
    Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy.
    Pan Y; Chen H; Zhang X; Liu W; Ding Y; Huang D; Zhai J; Wei W; Wen J; Chen D; Zhou Y; Liang C; Wong N; Man K; Cheung AH; Wong CC; Yu J
    Cell Rep Med; 2023 Aug; 4(8):101144. PubMed ID: 37586322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.